Navigation Links
10 Million Square Feet of Turf Set to be Treated in 2008 in Response to MRSA Outbreaks Nationwide
Date:1/8/2008

ROCHESTER HILLS, Mich., Jan. 8 /PRNewswire/ -- CSG/SportsCoatings, today announced approximately 10 million square feet of synthetic turf will be treated with its industry-leading antimicrobial coating, TurfAide(TM), in 2008 -- up from 1.5 million square feet in 2007.

The exponential increase in demand for TurfAide has been attributed to several factors, including a 2007 report in the Journal of the American Medical Association that found MRSA (methicillin-resistant Staphlycoccus aureas) is responsible for more than 94,000 serious infections and nearly 19,000 deaths each year. MRSA, a potentially deadly skin infection, is caused by staph bacteria that can survive on surfaces for days. The antimicrobial technology in TurfAide is proven to inhibit the growth of bacteria, fungi and mold for years with just one application.

According to three studies conducted by the Texas Department of State Health Services, the MRSA infection rate among football players is 16 times higher than the average person. Texas has synthetic turf at 18 percent of its high school fields.

"Schools, professional teams and recreation centers are recognizing the growing threat of sports-related infections," said CSG/SportsCoatings CEO Craig Andrews. "More synthetic turf systems will be treated with TurfAide than all other antimicrobial products combined in 2008; because it's a proven and powerful technology that's been safely used in medical and consumer goods for over 30 years."

"With bacterial infections like MRSA and fungi like ringworm affecting many student athletes across the country, the need to protect your facilities has become a necessity," said Jim Weaver, Virginia Tech University Athletics Director.

Virginia Tech University is one of many major Division I programs, National Football League franchises and high schools that have had their synthetic turf fields treated with TurfAide in the past 18 months. A small sampling of TurfAide clients includ
'/>"/>

SOURCE CSG/SportsCoatings
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Romark Laboratories Raises $18 Million in Institutional Financing
2. MJFF and Merck Serono (EMD Serono in North America) Join Forces on $2-Million Initiative to Drive Treatments for PD-Related Cognitive Dysfunction and Mood Disorders
3. NeuroVasx, Inc. Announces $8.5 Million Private Placement and Completion of cPAX Aneurysm Treatment Study
4. Five Clinical Studies to Receive $2.5 Million Under Foundations 2007 Clinical Discovery Program
5. Female Health Company Receives Brazilian Order: Four Million FC Female Condoms
6. Immtech Receives $5.1 Million to Further African Sleeping Sickness Clinical Trials
7. Coley Pharmaceutical Group Receives $3.0 Million Milestone Payment from GlaxoSmithKline
8. Paratek Pharmaceuticals Announces the Close of $40 Million Private Placement to Finance Programs to Combat MRSA Infections
9. 38.7 Million People Break Guinness World Record for Stand Up Speak Out on International Day for the Eradication of Poverty
10. National Jewish, Brigham and Womens Awarded $37 Million to Identify Genes and Other Risk Factors that Influence the Development of COPD
11. Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2008)...REXEL International Corporation (Nasdaq: PRXL ),...der, today announced that it has opened an office ... clinical research capabilities. With the addition...oughout five important biopharmaceutical centers i...zil, Chile, and Mexico. This expansion further str...
(Date:11/19/2008)... Science Corporation,researcher, Dan Tinker, pres...nual Conference in Washington, DC this week indica...mers. The computerized brain plasticity-based,Br...hat target auditory and,language systems. The ex...ments in cognition by improving speed and accuracy...
(Date:11/19/2008)...l significance , , ISELIN, N.J., Nov. 19 /...aq: PARS ) today announced results from its Phas...E) drug delivery technology formulated with 3% Dic...r, randomized, double-blinded, placebo-controlled ...pany,s 3% Diclofenac Diethanolamine NanoEmulsion c...
(Date:11/19/2008)...Biotech scientists increasingly are applying genom...understand the effects of novel drug candidates on...neering & Biotechnology News ( GEN ). They ar...ound,s mechanism of action and eventually developi... the November 15 issue of GEN . ( http://www.gene...
Breaking Medicine Technology:PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 2PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 3PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 4New Evidence That Brain-Plasticity Based Training has Broad Impact: Improved Cognition in Boomers, Improved Motor Control in Older Adults 2Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream 2GEN Reports on the Trend Toward Predictive Toxicogenomics 2Pharmacopeia to Present at the 15TH Annual Future Leaders in the Biotech Industry Conference 4097 1Pharmacopeia to Present at the 15TH Annual Future Leaders in the Biotech Industry Conference 4097 2Pharmacopeia to Present at the 15TH Annual Future Leaders in the Biotech Industry Conference 4097 3Pharmacopeia to Present at the 15TH Annual Future Leaders in the Biotech Industry Conference 4097 4IPC The Hospitalist Company Announces Board of Director Member Changes 14788 1IPC The Hospitalist Company Announces Board of Director Member Changes 14788 2IPC The Hospitalist Company Announces Board of Director Member Changes 14788 3IPC The Hospitalist Company Announces Board of Director Member Changes 14788 4IPC The Hospitalist Company Announces Board of Director Member Changes 14788 5IPC The Hospitalist Company Announces Board of Director Member Changes 14788 6IPC The Hospitalist Company Announces Board of Director Member Changes 14788 7IPC The Hospitalist Company Announces Board of Director Member Changes 14788 8IPC The Hospitalist Company Announces Board of Director Member Changes 14788 9IPC The Hospitalist Company Announces Board of Director Member Changes 14788 10IPC The Hospitalist Company Announces Board of Director Member Changes 14788 11IPC The Hospitalist Company Announces Board of Director Member Changes 14788 12IPC The Hospitalist Company Announces Board of Director Member Changes 14788 13IPC The Hospitalist Company Announces Board of Director Member Changes 14788 14Featured Stocks on Todays Edition of WallSt nets 3 Minute Press Show 3A INIX BPAX GLOW LB 14786 1Featured Stocks on Todays Edition of WallSt nets 3 Minute Press Show 3A INIX BPAX GLOW LB 14786 2Featured Stocks on Todays Edition of WallSt nets 3 Minute Press Show 3A INIX BPAX GLOW LB 14786 3Featured Stocks on Todays Edition of WallSt nets 3 Minute Press Show 3A INIX BPAX GLOW LB 14786 4MedCom Announces Court Rules Card Activation Technologies Patent Is Valid 14785 1MedCom Announces Court Rules Card Activation Technologies Patent Is Valid 14785 2MedCom Announces Court Rules Card Activation Technologies Patent Is Valid 14785 3
... WIRE)--Apr 16, 2007 - Novelos,Therapeutics, Inc. ... on the development of therapeutics to treat cance... in collaboration with,Dr. Kenneth Tew and Dr. Dan...Carolina (MUSC), is making two poster presentation...esearch annual meeting.,These presentations will h...
...IRE)--Apr 16, 2007 - ZIOPHARM Oncology,Inc. (NASD...indibulin (ZIO-301) at the American Association of...ese data demonstrate that,indibulin has distinct b...n binding agents and strongly suggest a very diffe... peripheral,neuropathy. While indibulin binds to t...
Other Medicine Technology:Novelos Therapeutics and MUSC Present Two Posters at AACR 2007,Annual Meeting 2ZIOPHARM Presents Unique Mechanism Data for Indibulin at AACR 2ZIOPHARM Presents Unique Mechanism Data for Indibulin at AACR 3
(Date:11/21/2008)...ective against Lennox-Gastaut syndrome , ...called Banzel (rufinamide) has been approved as a ...psy called Lennox-Gastaut syndrome, the U.S. Food ... approval was based on results of a four-month cli...ompared to patients who took a placebo, those who ...
(Date:11/21/2008)...re/ -- NursingCenter.com, the premier site,for on...d content, has been,updated to improve the intera.... Powered by Lippincott Williams & Wilkins (LW...reviewed continuing education activities and free,...ng nursing journals.,Lippincott Williams & Wi...
(Date:11/21/2008)...PRNewswire-FirstCall/ -- Today, prescription drugs...treating 88 percent of patients suffering chronic ...or a chronic condition account for 96 percent of a...l medical costs. A proprietary new pharmacy model...ons, Inc. (NYSE: MHS ) significantly reduces cri...
(Date:11/21/2008)... diseaseits cause remains a mysteryswept into Athe...itizens, soldiers and refugees of the war then rag...ith corpses, social order broke down. Over the nex...ns lost a third of its population. It lost the war... the end of the Golden Age of Greece. , The Pla...
Breaking Medicine News(10 mins):Health News:FDA Approves New Drug for Severe Epilepsy 2Health News:NursingCenter.com Launches New Features to Improve User Experience 2Health News:NursingCenter.com Launches New Features to Improve User Experience 3Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 2Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 3Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 4Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 5Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 6Health News:Study of ancient and modern plagues finds common features 2Health News:Study of ancient and modern plagues finds common features 3Health News:Study of ancient and modern plagues finds common features 4
...atest study researchers have observed that doctors...ood pressure and other cardiac risk factors in eth...tal, Georgia have carried out a population survey ...igins, looking at their heart disease and stroke r...
...of a patient can have a major impact on how suscep...id arthritis, according to new research. The publi...to factors// not related to the disease when they ...oubt being diagnosed with a chronic, disabling dis...
... alfa treats anaemia in cancer patients and thereb...ry common side effect of cancer chemotherapy. It r... the protein that carries oxygen round the body. T...lming exhaustion that is not relieved by rest. Pat...
...rve that a new topical medication can effectively ...he sun. They found that in a long-term study of ta...nkling and mottled skin in more than 55 percent// ...how additional benefit as the length of use increa...
Other Medicine News:Health News:Personality Impacts Arthritis 2
...ormance Tecoflex stents that save inventory, shelf...eteral Stents accommodate ureteral lengths from 22...ws the Quadra-Coil to glide over any guidewire and...provide ease of placement and patient comfort in a...
...temporary internal drainage from the ureteropelvic...is engineered for ease of placement and patient co... designed for repositioning and ease of removal. A... that when activated, attracts and holds water and...
The CMV IgM enzyme immunoassay is for the qualitative detection of antibodies to cytomegalovirus. The CMV IgM assay is primarily indicated for the detection of early or recent infection.
The Shandon Sequenza uses the Shandon Coverplate system which ensures consistency and excellent staining quality. , , ,Allows the user to perform large immunostaining runs (up to 50 slides/run
Medicine Products: